NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Sonoma Pharmaceuticals, Inc. SNOA
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$19.5M
▲ 36.7% vs FY2024
EPS · FY25
$-1.89
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-84.6%
Net margin · FY25
-16.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 19.5M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 16 cents on every revenue dollar this year.
Per share
USD -1.89
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-84.6%
Return on equity, FY2025
ROE
Operating margin-12.6%
Net margin-16.3%
Return on assets-23.0%
Each USD of equity lost 85 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+0.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+13.7%
+0.9%
+7.6%
+4.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 14.0M
total assets, end of FY2025
Total assetsUSD 14.0M
EquityUSD 3.1M
CashUSD 2.4M
Gross debtUSD 222,000.00
Net debtUSD -2.2M
Current ratio2.50×
The company holds more cash than debt.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.89
−2.79
−10.63
−1.52
−1.92
−1.97
−2.24
−12.77
−28.49
2.20
−3.09
−0.85
0.54
−1.30
−1.87
−0.30
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−84.6
−65.5
−68.5
−61.8
−72.3
−71.9
−49.4
−102.2
−78.0
58.8
−91.6
−68.0
46.3
−338.1
−1759.7
−467.3
Shares out B
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.02
0.01
0.01
0.00
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
64 of 64
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed